Medical Newswire

Medical Newswire!

Medicine, Healthcare, Medical Research, Hospitals, Management
Press release distribution service
Home | Medical-Newswire.Com:

RNAi Drug Delivery better than Nanoparticles Drug Delivery?

 



(Medical-NewsWire.com, August 14, 2018 ) Global RNAi Drug Delivery Market was worth USD 39.4 billion in 2018 and is expected to reach USD 131.2 billion by 2023 with a CAGR of 27.2 %.
RNAi is one of the most important methods of analysing gene functions in eukaryotes. It also plays a pivotal role in the development of therapeutic gene silencing. Gene silencing is a term refers to the ability of a cell to prevent the expression of a specific gene.

RNAi has application in the areas of therapeutics, drug delivery, innovative work and farming. The helpful utilization of RNAi incorporates metabolic activity, cardiology, neurology, oncology, and ophthalmology.

Based on the Geographical Segmentation, the worldwide market is dissected under different regions, in particular, North America, Europe, Asia-Pacific, Latin America and the Middle East and Africa. North America has the largest share in the market followed by Europe because of their high investments. However, Asia-Pacific market is expected to increase at highest CAGR in the following five years because of increasing investments by the major players in this region
Major Organisations in the Global RNAi Drug Delivery Market are Tekmira Pharmaceuticals Corp, Alnylam Pharmaceuticals Inc, Merck & Co Inc, Access Pharmaceuticals Inc, Dicerna Pharmaceuticals Inc, Isis Pharmaceuticals Inc, RXi Pharmaceuticals Corp, Marina Biotech Inc, Calondo Pharmaceuticals Inc, Tacere Therapeutics Inc, Silence Therapeutics plc, Traversa Therapeutics Inc, Quark Pharmaceuticals Inc, PhaseRx Inc, and Sirnaomics Inc.

Browse full research report with TOC on "RNAi Drug Delivery Market, by Drug Delivery (nanoparticle drug delivery technology, pulmonary drug delivery technology, nucleic acid drug delivery technology and aptamer drug delivery technology), by Therapeutic Application (infectious diseases, cardiology, oncology, neurology, ophthalmology and metabolic disorders)"

Market Data Forecast has segmented the Global RNAi Drug Delivery Market on the basis of, Drug Delivery, Therapeutic Application and region:
Drug Delivery Outlook (Volume, Kilograms; Revenue, USD Thousands; 2018-2023):
Nanoparticle drug delivery technology, pulmonary drug delivery technology, nucleic acid drug delivery technology and aptamer drug delivery technology

Customize Report: https://www.marketdataforecast.com/market-reports/global-rnai-drug-delivery-market-1976/customize-report

Infectious diseases, cardiology, oncology, neurology, ophthalmology and metabolic disorders

Request Sample: https://www.marketdataforecast.com/market-reports/global-rnai-drug-delivery-market-1976/request-sample

Regional Outlook (Volume, Kilograms, Revenue, USD Thousands; 2016-2021):
North America, Europe, Asia Pacific, Latin America, Middle East and Africa
Further Key Findings from the Report Suggest:
• Expanded research in the field of RNA therapeutics has powered the development of worldwide RNAi drug delivery market.
• Notwithstanding, high venture cost and stringent controls are a portion of the significant restrictions for the worldwide RNAi drug delivery market. Furthermore, directed delivery of RNA molecules is a key test for the worldwide RNAi drug delivery market.
• Numerous organizations occupied with creating RNA therapeutics are confronting troubles in the delivery of RNA atoms to particular tissues to achieve a restorative impact. Expanded research in the field of nanotechnology builds up an open door for the worldwide RNAi drug delivery market.
• Expanding mergers and coordinated efforts between life sciences organizations and government inquire about associations is a key pattern for the worldwide RNAi drug delivery market.

Contact Info:
Name: Mr. Abhishek Shukla
Email: abhishek@marketdataforecast.com
Organization: MarketDataForecast™
Phone: +1-888-702-9626
Email: abhishek@marketdataforecast.com



Market Data Forecast.

Abhishek Shukla

+1-888-702-9626

abhishek@marketdataforecast.com

Source: EmailWire.Com

Source: EmailWire.com


Medical Resources
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Healthcare resource center today to browse our selection of 600+ complimentary Healthcare magazines, white papers, webinars, podcasts, and more. Get popular titles including:

Eyecare Business
Medical Laboratory Observer
FierceHealthcare

No credit cards, coupons, or promo codes required. Try it today!

Medical Sponsors

Health News


Pharmanewswire.com is part of GropWeb Network, online properties of GroupWeb Media LLC. Copyright © GroupWeb Media LLC. All Rights Reserved.

For unlimited press release distribution for $99 per month, call (281) 645-4086 or start posting your press releases online at EmailWire.com. CityRegions.Com is part of GropWeb Network, online properties of GroupWeb Media LLC. Copyright © 2012 GroupWeb Media LLC. All Rights Reserved.


GroupWeb Media Network
AfricaNewswire.Net | AppleNews247.Com | AsiaNewsWire.Net | Aviation-NewsWire | Energy Industry | EstateNewsWire | Entertainment-NewsWire.com | Food Beverage News | Glamour NewsWire | Health NewsWire | Hosting NewsWire | i-Auto NewsWire | i-Business News | EuropeNewsWire.Net | iCameroon.com | i-Canada-News.Com | i-SoftwareNews.com | iT-NewsWire.Com
| InvestorsNewsDesk.Com | i-TravelNewsWire.Com | LegalLaw247.com | Medical-NewsWire.com | MiningNewsWire.net | MoneyNewsWire.Net | Movie-Stars-News.Com | PayDayNews247.Com | PharmaNewsWire.Com | Publishing-NewsWire.Com | Shopping-NewsWire.com | Telecom-NewsWire.Net | Transportation-News.Com | USGovernment-News.Com | WebPosters.Net | Wireless-NewsWire.Com |
Medical-Newswire.com - Medicl Newswire and Press Release service of GroupWeb Media LLC